⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VYGR News
Voyager Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
VYGR
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
globenewswire.com
VYGR
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
globenewswire.com
VYGR
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Form 8-K
sec.gov
VYGR
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
globenewswire.com
VYGR
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
prnewswire.com
BIOA
CRSP
VRTX
VYGR
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR